Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.

@article{Cappel2004SurvivalAA,
  title={Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.},
  author={Wouter H. de Vos tot Nederveen Cappel and Hielke J. Meulenbeld and Jan H. Kleibeuker and Fokko M. Nagengast and Fred H. Menko and Gerrit Griffioen and Annemiek Cats and Hans Morreau and Hans Gelderblom and Hans F A Vasen},
  journal={International journal of cancer},
  year={2004},
  volume={109 3},
  pages={
          468-71
        }
}
In vitro studies suggest that a deficient mismatch repair (MMR) system reduces 5-Fluorouracil cytotoxicity. Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI). Clinical studies on the efficacy of 5-Fluorouracil (5-FU) in MSI high tumours are contradictory. In a retrospective study, we compared the survival of subjects with stage III CC from HNPCC families that were treated with and without… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS, ESTIMATED 59% COVERAGE

FILTER CITATIONS BY YEAR

2004
2019